Although most colorectal cancers are adenocarcinomas, there are several histological types of colorectal cancers, such as neuroendocrine tumors (NETs), lymphomas, gastrointestinal tumors (GISTs), melanomas, squamous cell carcinoma, and sarcomas, accounting for 2%–6% of all colorectal cancers [1, 2]. Using a nationwide, population-based cancer registry, the authors investigated the incidence and clinical characteristics for these rare colorectal cancers [2]. This analysis was performed to update the incidences of rare histological types of colorectal cancers in South Korea. I believe that this analysis can facilitate further investigations regarding more accurate prognosis and clinical impact in the future.
NETs originate from the diffuse system of neuroendocrine cells and constitute 2% of all gastrointestinal (GI) malignancies [3]. Although colonic NETs are rare, their incidence has been increasing from 0.002 per 100,000 individuals in 1973 to 0.2 per 100,000 individuals in 2004, according to a western registry [4]. Approximately 70% of colonic NETs occur in the right colon, especially in the cecum [5]. Moreover, the incidence of rectal NETs has been increased 10-fold over the last 30 years, which is approximately 1 per 100,000 individuals [6]. A previous Korean study showed that the mean age at diagnosis of rectal NETs was 50 years and rectal NETs were somewhat more common in males than in females [7]. Complete resection of NETs is generally recommended according to their size, but other treatment options are also available [3].
GISTs are the most common GI mesenchymal tumors and account for 0.1%–3.0% of all GI malignancies [8, 9]. The annual incidence of GISTs is estimated to be 1–2 per 100,000 individuals [10]. The median age at diagnosis of GISTs is 60 years, and GISTs do not have any sex or race predominance [11]. Surgical resection remains the gold standard management for GISTs, and imatinib is currently used in the neoadjuvant, adjuvant, and metastatic disease setting [12].
Despite the rare occurrence of various colorectal nonadenocarcinomas, surgical resection is considered important for the cure. Further studies are needed to better understand the progression and long-term oncological outcomes of these rare tumors.
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was reported.
REFERENCESKangHO’ConnellJBLeonardiMJMaggardMAMcGoryMLKoCYRare tumors of the colon and rectum: a national review2007221839NamSKimDJungKChoiYJKangJGAnalysis of the incidence and clinical features of colorectal nonadenocarcinoma in Korea: a national cancer registry-based study2020363907AhmedMGastrointestinal neuroendocrine tumors in 2020202012791807CaplinMSundinANillsonOBaumRPKloseKJKelestimurFENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms2012958897AnthonyLBStrosbergJRKlimstraDSMaplesWJO’DorisioTMWarnerRRThe NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum20103976774BasuroyRHajiARamageJKQuagliaASrirajaskanthanRReview article: the investigation and management of rectal neuroendocrine tumours20164433245YoonSNYuCSShinUSKimCWLimSBKimJCClinicopathological characteristics of rectal carcinoids201025108792DeMatteoRPLewisJJLeungDMudanSSWoodruffJMBrennanMFTwo hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival2000231518NishidaTHirotaSBiological and clinical review of stromal tumors in the gastrointestinal tract2000151293301ScarpaMBertinMRuffoloCPoleseLD’AmicoDFAngrimanIA systematic review on the clinical diagnosis of gastrointestinal stromal tumors20089838492RautCPDeMatteoRPPrognostic factors for primary GIST: prime time for personalized therapy?20081546KelleyKAByrneRLuKCGastrointestinal stromal tumors of the distal gastrointestinal tract201831295300